Table 5. Comparison among studies on the topic.a .
| Characteristic | Study | ||||
|---|---|---|---|---|---|
| Shaefi et al. 7 | Zhang et al. 8 | Daviet et al. 9 | Lebreton et al. 12 | Present study | |
| Participants, N | 130 | 43 | 76 | 302 | 30 |
| Country | USA | UK | France | France | Brazil |
| Mortality rate | 34.6% | 32.6% | 38% | 54% | 33.3% |
| Age, years | 45 | 49 | 61 | 52 | 53 |
| More than two comorbidities | 31.6% | N/A | N/A | N/A | 50% |
| pH | N/A | N/A | 7.30 | 7.31 | 7.31 |
| Renal replacement therapy | 21.8% | 37.9% | 33% | 43% | 36.7% |
| Use of vasoactive drugs | N/A | 79.3% | N/A | N/A | 80% |
| SOFA score | N/A | 6 | 7 | 12 | 11 |
| RESP score | 3 | 4 | 1 | N/A | 2 |
| Ventilation use before ECMO, days | 2 | 5 | 6 | 5 | 4 |
| Pao2/Fio2 | 85 | 67.5 | 71.5 | 61 | 66 |
| Pulmonary compliance, cmH2O | 28 | N/A | 23 | N/A | 20 |
| Thrombosis | 22.6% | N/A | N/A | N/A | 0 |
| Circuit coagulation | N/A | N/A | 15% | 10% | 3.3% |
| Major bleeding | 24.7% | 18.6% | 57% | 43% | 33.3% |
| Hemorrhagic stroke | 4.2% | N/A | N/A | 12% | 10% |
| Severe thrombocytopenia | N/A | N/A | N/A | 18% | 23.3% |
ECMO: extracorporeal membrane oxygenation; and RESP: Respiratory ECMO Survival Prediction. aValues expressed as median, except where otherwise indicated.